RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post

Commentary on Twitter

https://twitter.com/DrYukselUrun/status/1600233075455143937